Case Study from The handbook

Challenging policy inertia for HF diagnosis: The Belgian Charter for Heart Failure

5 September, 2018

Natriuretic peptide (NP) testing is not always reimbursed in Belgium, despite being recommended in European guidelines as an important element of heart failure diagnosis. The Belgian Charter for Heart Failure demands reimbursement for guideline-recommended diagnostic tests as one of the five priorities for policy action. The initiative has been led by leading cardiac organisations and has been signed by 12,000 people to date.

Back to the Project
The Heart Failure Policy Network is made possible with financial support from Novartis Pharma, AstraZeneca and Vifor Pharma. The content produced by the Network is non-promotional and not biased to any specific treatment or therapy. All outputs are guided and endorsed by the Network’s members.